John J. Alam M.D. Joins Inhibitex as Senior Medical Advisor
April 01 2010 - 9:00AM
Business Wire
Inhibitex, Inc. (Nasdaq: INHX) today announced that John J.
Alam, M.D. has joined Inhibitex as its Senior Medical Advisor. Dr.
Alam was formerly Executive Vice President, Medicines Development
and Chief Medical Officer at Vertex Pharmaceuticals, Incorporated.
Dr. Alam will be responsible for formulating and directing the
clinical and regulatory strategies for Inhibitex’s development
programs, including FV-100, which is in Phase II clinical
development for the treatment of shingles, and INX-189, a
nucleotide polymerase inhibitor in development for the treatment of
chronic hepatitis C infections (HCV).
“John’s in-depth expertise in antiviral drug development will be
a valuable addition to our leadership team,” stated Russell H.
Plumb, President and CEO of Inhibitex, Inc. “In particular, his
recent experience with the clinical development of telaprevir, a
first-in-class HCV protease inhibitor that is currently in several
pivotal Phase III clinical trials, will be highly relevant as we
advance INX-189 into clinical development.”
Dr. Alam is a Distinguished Fellow at the Center for Biomedical
Innovation at the Massachusetts Institute of Technology (MIT). From
1997 to 2008, he held various positions of increasing
responsibility at Vertex, and was responsible for leading
telaprevir from preclinical to Phase III development. From 1991 to
1997, Dr. Alam held a number of positions with Biogen, Inc.,
including Director of Medical Research and Program Executive for
Avonex® (interferon beta-1a for multiple sclerosis).
Prior to joining the life science industry, Dr. Alam completed
an internal medicine residency at The Brigham and Women’s Hospital
and a research fellowship at the Dana-Farber Cancer Institute. He
holds an M.D. from Northwestern University Medical School and a
S.B. in chemical engineering from MIT.
About Inhibitex
Inhibitex, Inc., headquartered in Alpharetta, Georgia, is a
biopharmaceutical company focused on developing products to prevent
and treat serious infectious diseases. The Company’s pipeline
includes FV-100 and INX-189, as well as additional HCV nucleotide
polymerase inhibitors in preclinical development. The Company has
also licensed the use of its proprietary MSCRAMM® protein platform
to Pfizer for the development of staphylococcal vaccines. Pfizer
recently initiated patient recruitment for a 408-patient,
randomized, double-blind Phase I clinical trial to evaluate the
safety, tolerability and immunogenicity of a 3-antigen
Staphylococcus aureus (S. aureus) vaccine in healthy adults. For
additional information about the Company, please visit
www.inhibitex.com.
Inhibitex® and MSCRAMM® are registered trademark of Inhibitex,
Inc. Avonex® is a registered trademark of Biogen Idec, Inc.
Inhibitex, Inc. (MM) (NASDAQ:INHX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Inhibitex, Inc. (MM) (NASDAQ:INHX)
Historical Stock Chart
From Jul 2023 to Jul 2024